Myocardial infarction represents a major source of morbidity and mortality, and its occurrence will continue to increase as the population ages. Cell death during myocardial ischemia and reperfusion represents both necrosis and apoptosis. Cell injury can largely be prevented by preconditioning, in which a brief period of ischemia before a more sustained ischemia protects myocardium. The mechanism of preconditioning is incompletely understood, but is associated with preservation of ATP stores, preservation of mitochondrial structure, attenuation of cytoplasmic acidification through activation of the vacuolar proton ATPase, and perhaps additional mechanisms. Cardiomyocytes surviving an ischemic insult show an upregulation of Bcl-2. Bcl-2 is located in the outer mitochondrial membrane, and both Bcl-2 and mitochondria appear to play an important role in regulating apoptosis. Using isolated cardiomyocytes from adult rabbit heart, we have shown that apoptosis is a feature of cell death due to metabolic inhibition and recovery (simulated ischemia and reperfusion). This apoptosis can be prevented with a tripeptide inhibitor of the cystine protease family that cleave at aspartic acid residues (caspase). Moreover, we find that it is possible to protect cardiomyocytes by adding the caspase inhibitor after metabolic inhibition. This observation suggests that caspase activity does not become significant until during the recovery period. We hypothesize that 1) caspases are processed from the proenzyme to the catalytically active form during ischemia (metabolic inhibition), but that 2) they do not begin to cleave substrates until the recovery phase, that 3) preconditioning prevents caspase activation or attenuates caspase activity, and 4) preconditioning preserves mitochondrial function after ischemia, and 5) preservation of mitochondrial function is related to cell survival. These hypotheses are individually testable in our model. In this application we propose to examine the kinetics of caspase activation during ischemia and reperfusion, to identify which caspases are activated, to determine the relationship between preconditioning and caspase activation, and to evaluate mitochondrial function in relation to preconditioning and recovery from metabolic inhibition.
Gottlieb, Roberta A; Stotland, Aleksandr (2015) MitoTimer: a novel protein for monitoring mitochondrial turnover in the heart. J Mol Med (Berl) 93:271-8 |
Andres, Allen M; Stotland, Aleksandr; Queliconi, Bruno B et al. (2015) A time to reap, a time to sow: mitophagy and biogenesis in cardiac pathophysiology. J Mol Cell Cardiol 78:62-72 |
Andres, Allen M; Hernandez, Genaro; Lee, Pamela et al. (2014) Mitophagy is required for acute cardioprotection by simvastatin. Antioxid Redox Signal 21:1960-73 |
Pepe, Salvatore; Mentzer Jr, Robert M; Gottlieb, Roberta A (2014) Cell-permeable protein therapy for complex I dysfunction. J Bioenerg Biomembr 46:337-45 |
Mentzer Jr, Robert M; Wider, Joseph; Perry, Cynthia N et al. (2014) Reduction of infarct size by the therapeutic protein TAT-Ndi1 in vivo. J Cardiovasc Pharmacol Ther 19:315-20 |
Hernandez, Genaro; Thornton, Christine; Stotland, Aleksandr et al. (2013) MitoTimer: a novel tool for monitoring mitochondrial turnover. Autophagy 9:1852-61 |
Jahania, Salik M; Sengstock, David; Vaitkevicius, Peter et al. (2013) Activation of the homeostatic intracellular repair response during cardiac surgery. J Am Coll Surg 216:719-26; discussion 726-9 |
Gottlieb, Roberta A; Mentzer Jr, Robert M (2013) Autophagy: an affair of the heart. Heart Fail Rev 18:575-84 |
Giricz, Zoltan; Mentzer Jr, Robert M; Gottlieb, Roberta A (2012) Autophagy, myocardial protection, and the metabolic syndrome. J Cardiovasc Pharmacol 60:125-32 |
Gottlieb, Roberta A; Linton, Phyllis-Jean (2012) Indigestible mitochondria cause heartburn. Cell Res 22:1518-20 |
Showing the most recent 10 out of 56 publications